111608-65-2 Usage
Uses
Used in Pharmaceutical Industry:
1-[4-(5-Nitro-1H-indol-3-yl)-1-piperidinyl]ethanone is used as a pharmaceutical ingredient for its receptor antagonist properties, which are being studied for potential applications in the treatment of various medical conditions. Its ability to modulate receptor activity makes it a promising candidate for drug development.
Used in Drug Development Research:
In the field of drug development, 1-[4-(5-Nitro-1H-indol-3-yl)-1-piperidinyl]ethanone is utilized as a key component in the synthesis and design of new therapeutic agents. Its unique chemical structure allows researchers to explore its potential interactions with biological targets, paving the way for the creation of novel medications.
Used in Receptor Antagonist Studies:
1-[4-(5-Nitro-1H-indol-3-yl)-1-piperidinyl]ethanone is employed as a receptor antagonist in scientific research, where it is investigated for its ability to modulate receptor activity. This research is crucial for understanding the compound's potential therapeutic effects and for identifying new avenues for medical treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 111608-65-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,1,6,0 and 8 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 111608-65:
(8*1)+(7*1)+(6*1)+(5*6)+(4*0)+(3*8)+(2*6)+(1*5)=92
92 % 10 = 2
So 111608-65-2 is a valid CAS Registry Number.
111608-65-2Relevant academic research and scientific papers
Shigenaga,Manabe,Matsuda,Fujii,Hiroi,Matsuo
, p. 1589 - 1595 (1993)
A number of N-[4-[4-(1H-indol-3-yl)piperidinoalkyl]-2- thiazolyl]alkanesulfonamides (8-21) were synthesized and evaluated for their preventive effects on systemic anaphylaxis in guinea pigs. Structure-activity analysis revealed that methane- and ethanesulfonamide derivatives having a one to three methylene tether between the piperidine and thiazole rings exhibited potent activity but the introduction of a substituent on the indole part reduced the activity. Administration (100 mg/kg p.o.) of the four compounds 8, 9, 12, 13, together with ketotifen, oxatomide, terfenadine and azelastine as reference compounds, to mice revealed that only compound 8 caused no significant increase of the sleeping time induced by hexobarbital. In addition, compound 8 (10 mg/kg i.v.) did not change the electroencephalogram in conscious rabbits. These results led to the selection of N-[4-[4-(1H-indol-3-yl)piperidinomethyl]-2-thiazolyl]methanesulfonamide (8, FK613) for further development as a novel antiallergic agent. Clinical evaluation of FK613 is now in progress.
